当前位置:首页 期刊杂志

经鼻高流量氧疗对慢阻肺急性加重期患者的临床疗效观察和评价

时间:2024-05-13

王军

【摘要】目的:探討经鼻高流量氧疗对慢性阻塞性肺疾病急性加重期患者的临床疗效及预后的影响。方法:选取慢阻肺患者40例,随机分为治疗组和观察组,在常规药物治疗、护理等措施相同的基础上,前者予以经鼻高流量氧疗,后者予以传统氧疗,分别检测入院时和经治疗24h后的动脉血气分析、平均动脉压等指标,计算CURB-65和慢性阻塞性肺疾病和支气管哮喘生理评分,记录住院时间和28d再住院率,统计学分析比较相关指标。结果:两组患者在性别、年龄和治疗前的PH、PaO2、PaCO2比较差异无统计学意义(P>0.05),治疗后,PH、PaO2两组患者比较差异有统计学意义(P<0.05),治疗组患者三项指标组内比较差异有统计学意义(P<0.05);两组患者住院时间比较差异无统计学意义(P>0.05),28天再住院率比较差异有统计学意义(P<0.05)。BAP-65、CURB-65评分组内比较差异有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05)。结论:利用经鼻高流量氧疗可明显改善慢性阻塞性肺疾病急性加重期患者氧合状态,减少患者体内二氧化碳的蓄积,缓解呼吸性酸中毒,适用于伴二氧化碳蓄积的慢性阻塞性肺疾病急性加重期患者,且疗效和远期预后优于传统氧疗。

【关键词】慢性阻塞性肺疾病;急性加重期;经鼻高流量氧疗;血气分析

Clinical observation and evaluation of nasal high flow oxygen therapy in patients with acute exacerbation of chronic obstructive pulmonary disease

WANG Jun

Anqing Medical College of higher vocational school, Anqing, Anhui 246052, China

【Abstract】Objective:To investigate the effect of nasal high flow oxygen therapy on the clinical efficacy and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods: 40 patients with chronic obstructive pulmonary disease were randomly divided into treatment group and Observation Group. On the basis of routine drug treatment and nursing, the former was given high flow oxygen therapy through nose, the latter was given traditional oxygen therapy, arterial blood gas analysis and mean arterial pressure were measured at admission and 24 hours after treatment. Curb-65 and COPD and asthma physiological scores were calculated, the length of stay and 28-day readmission rate were recorded and analyzed statistically. Results: there was no significant difference between the two groups in terms of sex, age and PH、PaO2、PaCO2 before treatment(P>0.05). After treatment, there was significant difference in PH(P<0.05),PaCO2 between the two groups(P<0.05), there was no significant difference in the length of stay between the two groups(P>0.05), the 28-day readmission rate was significantly different(P<0.05). The scores of Bap-65 and CURB-65 were significantly different within groups(P<0.05), but not between groups(P>0.05). Conclusion: nasal high-flow oxygen therapy can improve oxygenation, reduce carbon dioxide accumulation and relieve respiratory acidosis in patients with acute exacerbation of chronic obstructive pulmonary disease, it is suitable for acute exacerbation of chronic obstructive pulmonary disease with carbon dioxide accumulation, and its curative effect and long-term prognosis are better than those of traditional oxygen therapy.

【Key Words】Chronic obstructive pulmonary disease; Acute exacerbation; Transnasal high flow oxygen therapy; Blood gas analysis

慢性阻塞性肺疾病进入急性加重期(Acute Exacerbation of Chronic Obstructive Pulmonary Disease,AECOPD)后,反复发作的咳嗽、喘闷、感染等表现严重影响了患者的生活质量并危及其生命安全。氧疗通过增加吸入的氧气浓度以提高吸入气体的氧分压,纠正低氧血症进而改善此类患者的临床症状,是目前常用的AECOPD治疗方法,但传统氧疗方式提供的吸入气体干燥、浓度偏低、患者耐受差,在纠正缺氧、高碳酸血症的临床效果不尽如人意[1]。目前,在急性低氧性呼吸衰竭、呼吸衰竭未行气管插管、心功能不全等临床病例中广泛使用了经鼻高流量氧疗(High Flow Nasal Cannula Oxygen therapy,HFNC)[2]。本研究旨在探讨在常规治疗、护理等措施的基础上,利用HFNC技术对AECOPD患者进行治疗,观察其与传统氧疗的临床疗效及预后差异,具体报告如下。

1 资料与方法

1.1 一般资料

选取2021年9月—2022年10月学校附院呼吸内科收治的AECOPD患者40例,随机分为治疗组和对照组,各20例。对照组,男11例,女9例,年龄57~78岁,平均年龄(67.25±8.12岁);治疗组,男6例,女14例,年龄57~78岁,平均年龄(62.56±10.62)岁;两组病例在性别、年龄比较上差异无统计学意义(P>0.05)。纳入标准:符合《慢性阻塞性肺疾病诊治指南(2013年修订版)》中相关标准,意识清醒,年龄在80岁以下,治疗前PH>7.25,PaO2<60mmHg或伴PaCO2>50mmHg,患者及其家属自愿参与本研究。排除标准:pH≤7.25,PaO2<40mmHg,PaCO2>65mmHg,需要进行重症监护、机械通气,合并有其他肺部疾病或严重心、肝、肾功能不全,近期有重大外伤或手术史,现在或曾经患有精神疾病或正在服用精神类药物,对治疗方法不耐受或中途退出者等。所有患者均签署知情同意书。

1.2 治疗方法

对照组接受传统氧疗,氧流量设为1~2L/min,治疗组接受HFNC治疗,氧浓度设为30%~50%,流量设为20~40L/min,温度设为37℃。均持续治疗24h以上。当PH≤7.25或PaO2<40mmHg或PaCO2>65mmHg,且2h无法纠正、意识障碍、呼吸困难、痰液增多排出困难、呼吸或心脏骤停的情况时停止氧疗,终止研究,另行治疗,本研究中未发现不良反应。两组除氧疗方式差异外,其他常规治疗、护理等处理措施相同。

1.3 指标观测及评分

入院后記录每位患者的基本资料,治疗前、24h后动脉血气分析等指标,记录患者住院时间、出院后28d内再住院率等。CURB-65(Confusion,Urea,Respiratory rate,Blood pressure,and Age,CURB-65)量表包括意识障碍、血尿素氮等5项指标。慢性阻塞性肺疾病和支气管哮喘生理评分((the COPD and Asthma Physiology Score,CAPS)量表包括心率、平均动脉压等8项指标,分别记分。所有数据双人录入。

1.4 数据统计

以MedCalc 20.218 统计学软件进行本研究的数数资料采用(%)表示,进行x2检验,计量资料采用(x±s)表示,进行t检验,P<0.05为差异具有统计学意义。

2 结果

2.1 治疗前后两患者血气分析的比较

治疗前,PH、PaO2、PaCO2两组患者比较差异无统计学意义(P>0.05),治疗后,PH、PaO2两组患者比较差异有统计学意义(P<0.05),PaCO2比较差异无统计学意义(P>0.05)。治疗组患者三项指标组内比较差异有统计学意义(P<0.05),见表2。

2.2 两组患者临床预后及评分比较

两组患者住院时间比较差异无统计学意义(P>0.05),28d再住院率比较差异有统计学意义(P<0.05)。BAP-65、CURB-65评分组内比较差异有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05),见表3。

3 讨论

AECOPD 住院患者的氧疗指征国内相关文献中均有明确规定,一般应以改善患者的低氧血症,保证动脉血氧饱和度(SaO2)在88%~92%为目标[3]。HFNC供给恒定浓度达21%~100%的氧气,可为患者提供加热加湿空氧混合气体,避免气道黏膜损伤[4-5],缓解炎症反应[6-7],增加潮气量,提高患者肺的换气效率,与传统氧疗相比,舒适度更高[8]。因此,HFNC被逐渐应用于AECOPD的临床实践。但AECOPD患者使用HFNC的适应证目前尚不明确[9]。本研究比较了HFNC与传统氧疗对AECOPD患者的临床疗效,结果发现,治疗组明显改善了AECOPD患者血氧指标,且优于对照组,表明HFNC治疗AECOPD能较好地缓解患者呼吸窘迫导致的缺氧状态。治疗24h后,对照组患者血气分析指标与治疗前比较差异无统计学意义,治疗组患者的PaCO2明显低于治疗前和对照组,进一步说明,HFNC可以减少AECOPD患者体内二氧化碳的蓄积,改善呼吸性酸中毒。同时,治疗组有效降低了患者28d再住院率,CURB-65、CAPS评分低于对照组,差异有统计学意义,HFNC远期疗效好于传统氧疗,这与国内外相关研究报道结论一致。

本研究结果显示了使用 HFNC对改善AECOPD患者临床症状和临床结局方面的一些优势,但研究样本总量有限、观察周期较短,未考虑患者基础疾病及药物因素的影响,因此,研究的初步结论需要进一步临床研究验证。

参考文献

[1] Nishimura M.High-flow nasal cannula oxygen therapy in adults [J].Intensive Care,2015,3(1):15.

[2] Hern ndez G,Vaquero C,Gonzalez P,et al.Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial[J].JAMA,2016,315(13):1354-1361.

[3] Lozano R,Naghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J].The Lancet,2012,380(9859):2095-2128.

[4] Maggiore Salvatore Maurizio,Idone Francesco Antonio,Vaschetto Rosanna,et al.Nasal high-flow versus Venturi mask oxygen therapy after extubation[J].Effects on oxygenation,comfort,and clinical outcome.2014, 190(3):282.

[5] Pisani L,Vega M L.Use of Nasal High Flow in Stable COPD:Rationale and Physiology[J].Copdjournal of Chronic Obstructive Pulmonary Disease,2017(15):1-5.

[6] Price D R,Zappetti D.The Physiological Effect of High-flow Nasal Cannula[J].Clinical Pulmonary Medicine,2017,24(5):224.

[7] Lee M K,Choi J,Park B,et al.High flow nasal cannulae oxygen therapy in acute‐moderate hypercapnic respiratory failure[J].Clinical Respiratory Journal,2018,75(7):256-258.

[8] Jing G,Li J,Hao D,et al.Comparison of high flow nasal cannula with noninvasive ventilation in chronic obstructive pulmonary disease patients with hypercapnia in preventing postextubation respiratory failure:A pilot randomized controlled trial[J].Research in Nursing & Health,2019,15(4):88-91.

[9] 劉霜,朱华栋,于学忠,等.经鼻高流量氧疗和无创正压通气对于肺源性中重度急性呼吸窘迫综合征患者初始治疗的效果评价[J].临床急诊杂志,2020,21(3):181-187.

免责声明

我们致力于保护作者版权,注重分享,被刊用文章因无法核实真实出处,未能及时与作者取得联系,或有版权异议的,请联系管理员,我们会立即处理! 部分文章是来自各大过期杂志,内容仅供学习参考,不准确地方联系删除处理!